MilliporeSigma
  • Home
  • Search Results
  • Modified lamellar keratoplasties for the treatment of deep stromal abscesses in horses.

Modified lamellar keratoplasties for the treatment of deep stromal abscesses in horses.

Veterinary ophthalmology (2014-10-15)
Richard J McMullen, Brian C Gilger, Tammy M Michau
ABSTRACT

To describe a surgical modification of deep lamellar endothelial keratoplasty (DLEK) and posterior lamellar keratoplasty (PLK) procedures, to facilitate surgery on standing horses under-sedation. Four client-owned horses, for which the owners declined surgery under general anesthesia, underwent standing corneal lamellar keratoplasty procedures for the treatment of deep corneal stromal abscesses. All four horses were placed in stocks and sedated with detomidine. Local eyelid and retrobulbar blocks were performed to provide local analgesia and akinesia, and each horse's head was stabilized and supported by soft pads placed on a mobile cart. Deep lamellar endothelial keratoplasties (DLEKs) and posterior lamellar keratoplasties (PLKs) were performed on two horses each, for the treatment of deep stromal abscesses (DSA). Following the first DLEK, a mid-stromal two-step anterior lamellar keratectomy modification was used to facilitate rapid closure of the anterior chamber immediately following removal of the abscess. Each of the four horses had similar cosmetic and postoperative visual outcomes, compared to previously published results. Intra-operative complications were most prevalent in the first DLEK case (i.e., focal iris and lens damage and postoperative anterior chamber collapse) and were all but eliminated in the remaining three cases. Similar to previously reported findings, greater postoperative corneal fibrosis was observed in the DLEK cases. In horses with deep stromal or endothelial abscesses, for which general anesthesia is not an option, both the modified DLEK and PLK corneal procedures may be performed as an alternative to enucleation on the standing, sedated horse.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Atropine, ≥99% (TLC), powder
Sigma-Aldrich
Hydrochloric acid, 36.5-38.0%, BioReagent, for molecular biology
Supelco
Hydrochloric acid solution, volumetric, 0.1 M HCl (0.1N), endotoxin free
Sigma-Aldrich
Hydrochloric acid solution, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
Hydrogen chloride solution, 3 M in cyclopentyl methyl ether (CPME)
Sigma-Aldrich
Fluconazole, ≥98% (HPLC), powder
Sigma-Aldrich
Hydrochloric acid solution, 32 wt. % in H2O, FCC
Sigma-Aldrich
Hydrochloric acid solution, ~6 M in H2O, for amino acid analysis
Sigma-Aldrich
Voriconazole, ≥98% (HPLC)
Sigma-Aldrich
Flunixin meglumine, ≥98% (HPLC)
Sigma-Aldrich
Omeprazole, solid
Sigma-Aldrich
Atropine sulfate salt monohydrate, ≥97% (TLC), crystalline
Sigma-Aldrich
Hydrogen chloride, ReagentPlus®, ≥99%